Core Insights - The growth of fund scale is increasingly influenced by product style clarity and predictable holdings rather than just performance metrics [1][7][8] - Despite high performance, many funds are experiencing a disconnect between returns and scale, with some funds achieving significant scale growth despite lower returns [2][4] Fund Performance and Scale - As of November 2, 2025, the highest-performing pharmaceutical fund achieved a return of 118%, yet its scale was only approximately 530 million [2] - Other funds with lower returns, such as 中银港股通医药基金 and 永赢医药创新智选, have significantly larger scales, indicating a trend where performance does not guarantee scale growth [2] Market Dynamics - The public fund market is seeing a diversification of product types, leading to increased scrutiny from investors regarding fund selection criteria [1][7] - The influx of capital into pharmaceutical funds has become a norm, with many funds experiencing substantial scale increases despite not being the top performers [1][2] Fund Manager Influence - The performance of "twin funds" managed by the same fund manager shows that better returns do not always correlate with larger scale, highlighting the importance of product positioning [4][6] - Fund managers' strategies and the transparency of their holdings are critical factors influencing investor interest and fund scale [7][8] Investor Preferences - Investors are increasingly favoring funds with stable styles and transparent holdings, which has led to a rise in the popularity of index funds due to their predictability [7][8] - The lack of mandatory investment restrictions in fund contracts can lead to decreased investor confidence, impacting fund scale despite strong performance [3][7]

Core Insights - The investment selection process among investors has become more rigorous, with a preference for products that exhibit clear styles and predictable holdings [1][3] - Despite high returns, some high-yield products struggle to attract capital, indicating a shift in investor focus towards stability and transparency [1][3] Group 1: Fund Performance and Capital Inflows - A significant amount of capital has flowed into the pharmaceutical fund sector in Q3 2023, with many funds exceeding 1 billion yuan in size, driven by strong performance [1] - The top-performing pharmaceutical fund from a leading public fund achieved a return of 118% year-to-date, yet its size remains only about 530 million yuan [1] - Other funds with lower returns, such as the Bank of China Hong Kong Stock Connect Pharmaceutical Fund, have larger sizes, indicating a disconnect between performance and capital attraction [1] Group 2: Manager Performance and Fund Size Discrepancies - Similar funds managed by star fund managers show stark differences in capital size despite similar performance, highlighting investor preferences [2] - For instance, the Ping An Core Advantage Fund has a return of 75% but only 245 million yuan in size, while the Ping An Medical Health Fund, with a lower return of 67%, has grown to 4.152 billion yuan [2] - This trend is also seen with manager Zhao Bei, where the better-performing fund has a size of less than 400 million yuan, while the underperforming fund exceeds 10 billion yuan [2] Group 3: Investor Preferences and Market Trends - Investors are increasingly favoring funds with stable styles and transparent holdings, leading to a surge in index fund popularity due to their predictability [3] - The public fund industry is experiencing a diversification of product offerings, with a rapid increase in segmented and scenario-based demands [3] - Predictability in fund holdings has become a key factor for attracting capital, often outweighing performance metrics [3]

Core Insights - Investors are increasingly selective in choosing public funds, prioritizing clear product styles and predictable holdings, leading to a disparity in fund inflows despite high returns [1][3] - The pharmaceutical fund sector has seen significant inflows, with some funds exceeding 1 billion yuan in size, while high-yield products struggle to attract capital despite strong performance [1] Group 1: Fund Performance and Size - The top-performing pharmaceutical fund reported a year-to-date return of 118% but had a size of only approximately 530 million yuan as of September 30 [1] - Other funds with lower returns, such as the Bank of China Hong Kong Stock Connect Pharmaceutical Fund and others, had sizes of 2.403 billion yuan, 8.383 billion yuan, 2.276 billion yuan, 1.587 billion yuan, and 1.606 billion yuan respectively, despite lower performance [1] Group 2: Manager Performance Discrepancies - Star fund manager Zhou Sicong's two similar pharmaceutical funds showed a stark contrast in size, with the core advantage fund at 245 million yuan and the healthcare fund at 4.152 billion yuan, despite the former having a higher return of 75% [2] - Similarly, manager Zhao Bei's funds had a performance gap of 50 percentage points, yet the underperforming fund exceeded 10 billion yuan in size while the better-performing fund remained below 400 million yuan [2] Group 3: Investor Preferences - The current market environment has led investors to favor funds with stable styles and transparent holdings, contributing to the growth of index funds due to their higher predictability [3] - Investors tend to prefer funds with predictable holdings, especially those mandated by fund contracts, over performance metrics when faced with similar products [3]

Core Viewpoints - The current bull market in A-shares is likely to continue, with market valuations remaining reasonable despite significant gains this year [3][7][10] Group 1: Fund Performance and Holdings - The performance of several funds, including融通产业趋势, 平安核心优势, and 万家趋势领先, has been notable, with year-to-date net value increases of 93.69%, 88.95%, and nearly 80% respectively [5][10][12] - Key holdings in融通产业趋势 include海博思创, 工业富联, and 中际旭创, with significant year-to-date price increases of 313.46%, 218.92%, and 301.99% respectively [5][6] - 平安核心优势 has focused on innovative pharmaceuticals, with major holdings like 康方生物 and 信达生物 showing year-to-date gains of 89% and 133.74% [8][10] Group 2: Investment Trends and Strategies - Investment managers are optimistic about sectors such as artificial intelligence, energy storage, and the internet, indicating a shift from pessimistic to reasonable valuations in the tech growth sector [4][7] - 万家趋势领先's strategy for the fourth quarter includes focusing on industrial non-ferrous metals and precious metals, anticipating price increases due to global economic shifts and supply chain restructuring [12][13] - The report highlights a trend towards innovative drugs entering the performance release cycle, with a significant portion of these companies expected to achieve profitability this year [10]

Core Viewpoint - The article highlights that pharmaceutical-themed funds have emerged as the top performers in the public fund market for the first half of 2025, with a significant focus on Hong Kong stocks and a concentrated investment strategy in specific sectors like oncology and metabolic diseases [2][5][7]. Group 1: Performance Rankings - In the first half of 2025, seven out of the top ten performing public funds were pharmaceutical-themed, with the top fund, Huatai-PB Hong Kong Advantage Selected Fund, achieving a return of 86% [3][5]. - Other notable funds in the top ten include CITIC Securities North Exchange Selected Fund and Great Wall Pharmaceutical Industry Selected Fund, with returns of 82.45% and 75.18% respectively [3][5]. - The top ten funds all had returns exceeding 61%, indicating a strong performance across the board [3]. Group 2: Investment Strategies - Nine out of the top ten funds employed a single-sector investment strategy, demonstrating the effectiveness of this approach in achieving high performance [4]. - The only fund that adopted a balanced strategy, the Great Wall Growth Leading Fund, still managed to achieve a return of 68.29% despite its diversified holdings [4]. Group 3: Importance of Hong Kong Stocks - The allocation to Hong Kong stocks, particularly in the innovative pharmaceutical sector, has been crucial for the performance of these funds [5][6]. - The top-performing funds have significantly increased their exposure to Hong Kong pharmaceutical stocks, with the Huatai-PB fund allocating 86% of its holdings to this sector [5][6]. - The trend indicates a blurring of lines between A-share and Hong Kong fund definitions as A-share funds increasingly allocate to Hong Kong stocks due to better valuation and growth prospects [5][6]. Group 4: Market Dynamics and Future Outlook - The innovative pharmaceutical sector is expected to continue leading market performance, driven by policy support, capital influx, and industry momentum [7][9]. - The article notes that the differences between Hong Kong and A-share markets are narrowing, with both markets benefiting from similar valuation dynamics and capital flows [8]. - The long-term outlook for companies with strong R&D capabilities and significant product potential remains positive, despite short-term volatility [9].

Core Insights - The article highlights that pharmaceutical-themed funds have emerged as the top performers in the public fund rankings for the first half of 2025, with seven out of the top ten funds being focused on this sector [1][2][4]. Group 1: Fund Performance - The top-performing fund, Huatai-PineBridge Hong Kong Advantage Select Fund, achieved a cumulative return of 86% in the first half of 2025, leading the market [2]. - Other notable funds include CITIC Securities North Exchange Select Fund and Great Wall Pharmaceutical Industry Select Fund, with returns of 82.45% and 75.18% respectively [2]. - The top ten funds all had returns exceeding 61%, with a significant concentration in pharmaceutical investments [2][4]. Group 2: Investment Strategies - Nine out of the top ten funds employed a single-track investment strategy, indicating that this approach has become a key method for fund managers to achieve high performance [3]. - The only fund that adopted a balanced strategy, the Great Wall Growth Leading Fund, still managed to achieve a return of 68.29% despite diversifying across multiple sectors [3]. Group 3: Focus on Hong Kong Stocks - The article emphasizes that the allocation to Hong Kong's innovative pharmaceutical stocks is crucial for fund performance, with the top funds heavily invested in this area [4][5]. - For instance, the Great Wall Pharmaceutical Industry Select Fund had a Hong Kong stock allocation of 35.20% as of March 2025, while the Ping An Core Advantage Fund approached 40% [4]. Group 4: Market Dynamics - The article discusses the increasing attractiveness of Hong Kong's innovative pharmaceutical sector compared to A-shares, driven by better fundamentals and valuation [4][6]. - The convergence of risk-return characteristics between Hong Kong and A-share markets is noted, with both benefiting from the same market trends [7][8]. Group 5: Future Outlook - The innovative pharmaceutical sector is expected to continue its strong performance, driven by policy incentives, capital influx, and industry momentum [6][8]. - The article suggests that companies with core R&D capabilities and significant product potential will continue to create value, presenting investment opportunities in the evolving market landscape [8].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - This week, the equity market showed differentiation, with the BeiZheng 50 leading the gains and the small - cap value style outperforming. In terms of industries, comprehensive finance led, and national defense and military industry, medicine, agriculture, forestry, animal husbandry and fishery also performed well. The bond market declined overall, while the convertible bond market rose. The average return of active equity funds in the whole market was - 0.41%; the average return of short - term bond funds was - 0.01%, and that of medium - and long - term bond funds was - 0.03%; the average return of bond funds with equity exposure was negative, and the average return of convertible bond funds was positive [1][2]. 3. Summary According to the Directory 3.1 Market Review - The equity market was differentiated, with the BeiZheng 50 leading and the small - cap value style dominant. Comprehensive finance led the industry performance, and national defense and military industry, medicine, agriculture, forestry, animal husbandry and fishery also performed well. As of the close this week, the CSI 300 Index closed at 3840 points, down 1.08%; the Shanghai Composite Index closed at 3347 points, down 0.03%; the Shenzhen Component Index closed at 10041 points, down 0.91%; the ChiNext Index closed at 1993 points, down 1.4%. In the Hong Kong stock market, the Hang Seng Index fell 1.32%, and the Hang Seng Tech Index fell 1.46% [6]. - In terms of industry performance, comprehensive finance led with a gain of over 10%. National defense and military industry, medicine, agriculture, forestry, animal husbandry and fishery performed well, while the automobile, non - ferrous metals, power equipment and new energy sectors declined by over 2% [8]. - As of May 30, 2025, there were 5413 stocks in the A - share market, of which 3228 stocks rose this week. The number of rising stocks on the BeiZheng, ChiNext, Science and Technology Innovation Board, and Main Board was 194, 816, 343, and 1875 respectively [11]. 3.2 Key Fund Tracking 3.2.1 Active Equity - **Fund Performance**: The average return of the whole - market funds in the sample was - 0.41%. Funds with better performance were heavily invested in industries such as medicine, non - ferrous metals, and food and beverages. Among industry - themed funds, medical sector funds had the highest average return, while mid - stream manufacturing and cyclical sector funds lagged [17][20]. - **Position Estimation**: This week, the positions of ordinary stock - type funds increased slightly, while those of partial - stock hybrid funds decreased slightly. Compared with the previous week, the positions of ordinary stock - type funds increased by 0.22 percentage points, and those of partial - stock hybrid funds decreased by 0.60 percentage points. Actively managed partial - stock funds increased their allocation to cyclical and stable sectors and reduced their allocation to financial, consumer, and growth sectors [23]. 3.2.2 Bond - type Funds - **Bond Market Performance**: The bond market declined overall this week. The ChinaBond Total Wealth Index closed at 245.89, down 0.07% from last week; the ChinaBond Treasury Bond Index closed at 246.62, down 0.07% from last week; the ChinaBond Credit Bond Index closed at 223, down 0.01% from last week. The CSI Non - Pure Bond Fund Index closed at 2184.93 on Thursday, down 0.02% from last Thursday. The CSI Convertible Bond Index closed at 429.31, with a weekly increase of 0.46% and a trading volume of 277.1 billion yuan, an increase of 2.093 billion yuan from last week [29][31]. - **Fund Performance Overview**: The average return of short - term bond funds was - 0.01%, and the median was - 0.01%. The average return of medium - and long - term bond funds was - 0.03%, and the median was - 0.04%. The average return of first - tier bond funds was 0%, and the median was - 0.01%. The average return of second - tier bond funds was - 0.02%, and the median was - 0.01%. The average return of partial - bond hybrid funds was - 0.03%, and the median was - 0.02%. The average return of low - position flexible allocation funds was - 0.07%, and the median was - 0.05%. The average return of convertible bond funds was 0.28%, and the median was 0.22% [34][37][40]. 3.2.3 New - share Subscription Funds - **New - share Overview**: One new stock was listed this week, with a total raised capital of 604 million yuan. There was no break - even on the first day of listing, and the expected total入围 income was 35,400 yuan [41]. - **New - share Subscription Income Calculation**: Assuming weekly participation in offline new - share subscriptions and successful入围, the weekly new - share subscription return sequence of an 800 - million - yuan account was calculated [42]. - **Fund Company New - share Subscription Overview**: Eight fund companies with more than two new - share subscription funds were selected. This week, the new - share subscription return rate of an 800 - million - yuan account was 0.004%. The optimal scale for weekly and annual new - share subscriptions was 400 million yuan [44]. - **New - share Subscription Fund Performance**: The average return of new - share subscription funds in the sample this week was - 0.18% [46]. 3.2.4 FOF Fund Performance - The average returns of low - risk, medium - risk, and high - risk FOF funds in the sample this week were - 0.28%, - 0.88%, and - 1.45% respectively [48]. 3.2.5 QDII Funds - During the statistical period, partial - stock and index QDII funds declined by 0.71% and 0.83% on average respectively, while alternative and bond QDII funds rose by 0.02% and 0.37% on average respectively [2][49]. 3.2.6 REITs Funds - This week, REITs declined by 0.02% on average. The Huaxia TBEA New Energy REIT led the gains, rising 4.26% this week. The Huatai Suzhou Hengtai Rental Housing REIT had the highest liquidity, with a trading volume of 130.2489 million yuan this week [51].

Core Viewpoint - The "pure pharmaceutical" funds have achieved the best performance among public QDII funds, highlighting a significant shift in investment focus away from popular AI and technology sectors towards undervalued pharmaceutical stocks [1][2][3] Group 1: Performance of Pharmaceutical Funds - As of March 5, the Huatai-PineBridge Hong Kong Advantage Select Fund achieved a year-to-date return of 23%, ranking first among Hong Kong and QDII funds, with a significant portion of its assets (89%) allocated to pharmaceutical stocks [2][3] - Other funds, such as the Jiashi Mutual Fund and Ping An Core Advantage Fund, also reported strong performances with returns of 22% and 20% respectively, focusing entirely on pharmaceutical stocks without exposure to AI or internet healthcare [4][5] Group 2: Market Dynamics and Trends - The shift towards pharmaceutical stocks by fund managers indicates a strong confidence in the recovery of this sector, despite the popularity of AI and technology stocks [4][6] - Non-pharmaceutical funds have begun to reallocate their portfolios towards pharmaceutical stocks, reflecting a trend of recognizing the potential for growth in this sector [6][12] Group 3: Technological Breakthroughs and Global Market Impact - Chinese pharmaceutical companies are experiencing significant breakthroughs, as evidenced by the collaboration between Kangfang Bio and Summit Therapeutics, which has led to a dramatic increase in stock prices [8][9][10] - The share of Chinese pharmaceutical companies in global drug transactions has increased from less than 5% in 2020 to over 20% in 2024, indicating a growing influence in the global pharmaceutical market [9][10] Group 4: Future Outlook for the Pharmaceutical Sector - The introduction of new drugs into the medical insurance system, with a majority being newly listed products, suggests a positive trend for domestic pharmaceutical innovation [12][13] - The anticipated role of commercial insurance in supporting innovative drugs is expected to enhance market dynamics and pricing strategies, further benefiting the pharmaceutical sector [13][14]